Home | Value-Based Cancer Care

Featured Content

Featured Video

The Future of Cancer Care Delivery

The future of cancer care delivery is shifting from fee-for-service to a value-based care approach.

View Content
Featured Article

Expert Insights on Innovation in the Oncology Pipeline

Total growth in the oncology pipeline in 2020 has been driven by targeted therapies, said Doug Long, Vice President, Industry Relations, IQVIA, at the 10th Annual Summit of the Association for Value-Based Cancer Care (AVBCC) in 2020.

View Content
Listen to our AVBCC Podcasts

Now you can take the Association for Value-Based Cancer Care (AVBCC) on the go with AVBCC podcasts. As healthcare professionals, it can be hard to find time in your busy schedule to stay up-to-date on oncology trends. Now you can receive trusted information from top industry leaders in an easy-to-listen format.

View Content

Top Trending Articles

1.

Oral Relugolix Equals Standard ADT, Slashes Cardiac Events in Patients with Advanced Prostate Cancer

2.

Durvalumab plus Chemotherapy New Standard of Care for Extensive-Stage Small-Cell Lung Cancer

3.

Cabozantinib plus Atezolizumab Combination Shows Meaningful Activity in Metastatic Prostate Cancer

FDA Approvals, News & Updates

FDA Approves Tepmetko for Metastatic NSCLC and MET Exon 14 Skipping Alterations

Orgovyx First FDA-Approved Oral Hormone Therapy for Advanced Prostate Cancer

FDA Approves Margenza for Treatment of Metastatic HER2-Positive Breast Cancer

View More Articles

Highlights from the Latest Issue: February 2021, Vol 12, No 1

February 2021, Vol 12, No 1

ASH 2020 Presidential Symposium Highlights Innovations Aimed to Improve Patient Access to Treatment

By Wayne Kuznar

Ruxolitinib in Graft-versus-Host Disease: Practice-Changing Results

By Phoebe Starr

Asciminib, First-in-Class STAMP Inhibitor, Superior to Bosutinib in Chronic-Phase CML

By Phoebe Starr

First-Line Mosunetuzumab Safe and Effective in Older Patients with Diffuse Large B-Cell Lymphoma

In the Literature

Sitagliptin, DPP-4 Inhibitor, Reduces the Incidence of Acute GVHD After Stem-Cell Transplant

Acute graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem-cell transplant (HSCT). The rate of GVHD is between 34% and 51% within 100 days of undergoing transplant.

Quick Quiz: Chronic Myeloid Leukemia

Quick Quiz: Chronic Myeloid Leukemia

Chronic myeloid leukemia, also known as chronic myelogenous leukemia, is a malignancy that originates in blood-forming cells (called myeloid cells) found in bone marrow. How much do you know about chronic myeloid leukemia?

Value-Based Care

ASH 2020 Presidential Symposium Highlights Innovations Aimed to Improve Patient Access to Treatment

Financial Toxicity Intervention in Patients with Hematologic Malignancies Effective, Improves Adherence and Quality of Life

The Future of Cancer Care Delivery

Rani Khetarpal, MBA

Financial Toxicity Can Be Deadly for Patients with Cancer

View More Articles

Personalized Medicine | Browse By Specialty

We Want to Know

Latest Videos

AVBCC Celebrates World Cancer Day

AVBCC Celebrates World Cancer Day

By Burt Zweigenhaft, PhD, D.Litt

Benefits and Challenges of a 2-Sided Risk Model

Benefits and Challenges of a 2-Sided Risk Model

By Rani Khetarpal, MBA

OCM Payment Methods

OCM Payment Methods

By Rani Khetarpal, MBA

View More Videos

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve:

VBCC Print Edition

VBCC Weekly e‑Newsletter

I have reviewed and consent to the terms of VBCC's Privacy Policy, and VBCC has my permission to retain my information in its database, and to forward pertinent communications to me.